Excess glucocorticoid levels in Cushing’s syndrome induces whole-body metabolic changes that are likely mediated by an inter-communication between different…
Articles by Patricia Inácio, PhD
Recordati‘s U.S. marketing rights for Cushing’s disease medications Signifor (pasireotide) and Signifor LAR…
More than 70% of patients have been enrolled in Strongbridge Biopharma’s Phase 3 LOGICS clinical trial assessing the safety and…
Fat accumulation in muscles caused by Cushing’s syndrome leads to impaired muscle function and worse physical performance long after…
Recordati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for…
On average, people with Cushing’s syndrome wait 34 months before receiving a definite diagnosis, but waiting time largely depends…
A Phase 3 trial evaluating Corcept Therapeutics‘ relacorilant in treating the high blood pressure and poorer glucose tolerance in…
A European Medicines Agency (EMA) committee has recommended the approval of osilodrostat — to be marketed as…
Surgically removing both adrenal glands is a safe and effective way to control excessive cortisol levels in people with…
Positron emission tomography (PET) scans help identify neuroendocrine tumors causing ectopic Cushing’s syndrome in patients whose disease persisted…